ARRY - Array BioPharma Inc.
| Previous Close | 15.45 |
| Open | 15.87 |
| Bid | 16.22 x 1400 |
| Ask | 16.23 x 800 |
| Day's Range | 15.76 - 16.31 |
| 52 Week Range | 10.54 - 20.21 |
| Volume | 1,652,094 |
| Avg. Volume | 2,532,615 |
| Market Cap | 3.45B |
| Beta (3Y Monthly) | 1.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.64 |
| Earnings Date | Feb 4, 2019 - Feb 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.00 |
- Insider Monkey•3 days ago
Is Array Biopharma Inc (ARRY) A Good Stock To Buy?
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed heavily on the minds of investors. Both the S&P 500 and Russell 2000 sank as a result, with the Russell 2000, […]
Markit•8 days agoSee what the IHS Markit Score report has to say about Array Biopharma Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Market Realist•12 days agoAnalysts Remain Bullish on Array BioPharma Stock
In November, of the total eight analysts covering Array BioPharma (ARRY), four analysts have given Array stock “strong buy” ratings, and four have given it “buy” ratings.
Market Realist•12 days agoUnderstanding Array BioPharma’s Operational Performance
Array BioPharma (ARRY) incurred a cost of goods sold of $195,000 in the first quarter of fiscal 2019. For fiscals 2019 and 2020, the company’s gross margins are expected to be 96.93% and 95.97%, respectively. In comparison, the fiscal 2019 gross margins of its peers Amgen (AMGN), Johnson & Johnson (JNJ), and Pfizer (PFE) are expected to be 85.68%, 70.65%, and 79.31%, respectively.
- Market Realist•12 days ago
An Overview of Array BioPharma Stock
Array BioPharma (ARRY) is focused on developing and marketing targeted small molecule drugs for treating patients with cancer and other high burden diseases.
Markit•15 days agoSee what the IHS Markit Score report has to say about Array Biopharma Inc.
Array Biopharma Inc NASDAQ NMS:ARRY
- PR Newswire•22 days ago
Array BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
BOULDER, Colo. , Nov. 20, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 30 th Annual Piper Jaffray Healthcare ...
- American City Business Journals•26 days ago
9 Colorado companies make Deloitte’s list of fastest-growing tech companies
Of the nine Colorado companies on the list, five are software companies and two are in biotech or pharmaceuticals.
- Simply Wall St.•27 days ago
Array BioPharma Inc (NASDAQ:ARRY) Is Trading At A 48.17% Discount
Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Array BioPharma Inc (NASDAQ:ARRY) as an investment opportunity by taking the Read More...
Markit•27 days agoSee what the IHS Markit Score report has to say about Array Biopharma Inc.
Array Biopharma Inc NASDAQ NMS:ARRY
Markit•last monthSee what the IHS Markit Score report has to say about Array Biopharma Inc.
Array Biopharma Inc NASDAQ NMS:ARRY
- Thomson Reuters StreetEvents•last month
Edited Transcript of ARRY earnings conference call or presentation 30-Oct-18 1:00pm GMT
Q1 2019 Array Biopharma Inc Earnings Call
- PR Newswire•last month
Array BioPharma to Present at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference
BOULDER, Colo. , Nov. 6, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Stifel 2018 Healthcare Conference and ...
Market Realist•last monthHow Wall Street Analysts View Exelixis
Exelixis (EXEL) reported net income of $126.6 million in the third quarter compared to $81.4 million in the third quarter of 2017. The company’s net income over the first nine months of this year amounted to $330.0 million compared to $115.7 million in the same period the prior year.
- GlobeNewswire•last month
Analysis: Positioning to Benefit within Array BioPharma, SPX FLOW, Holly Energy Partners, Electro Scientific Industries, Leggett & Platt, and CBL & Associates Properties — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- MarketWatch•last month
Harry Boxer’s four stocks to watch this week
• Array BioPharma (ARRY) gained $1.16 to $16.20 Wednesday after posting quarterly results that topped Wall Street expectations. The move broke the stock out above key lateral resistance as it has emerged from a head-and-shoulders bottoming pattern. Volume of 6.5 million shares was the biggest for the drug developer since May when its stock last broke out.
Markit•last monthSee what the IHS Markit Score report has to say about Array Biopharma Inc.
Array Biopharma Inc NASDAQ NMS:ARRY
- Motley Fool•last month
Why Array BioPharma Is Soaring Today
Shares jump after the company reports an upbeat start to its fiscal year.
- Zacks•last month
Array BioPharma (ARRY) Reports Q1 Loss, Tops Revenue Estimates
Array BioPharma (ARRY) delivered earnings and revenue surprises of 42.86% and 59.55%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Array BioPharma: Fiscal 1Q Earnings Snapshot
On a per-share basis, the Boulder, Colorado-based company said it had a loss of 12 cents. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment ...
- PR Newswire•last month
Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019
- Strong launch quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $14 million in net sales - - European Commission approves BRAFTOVI + MEKTOVI for advanced BRAF-mutant melanoma ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Array Biopharma Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Array BioPharma
NEW YORK, NY / ACCESSWIRE / October 26, 2018 / U.S. equities bounced back on Thursday supported mostly by gains in consumer discretionary and technology shares. The Dow Jones Industrial Average jumped ...
- PR Newswire•2 months ago
Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2019 on October 30, 2018
BOULDER, Colo. , Oct. 23, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2019 and hold a conference call to discuss those results ...
- Zacks•2 months ago
Array BioPharma (ARRY) Q1 Earnings Preview: What to Watch Ahead of the Release
Array BioPharma (ARRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
